MEDIVIR TRANSFERS THE LICENSING RIGHTS OF MIV-160

MEDIVIR TRANSFERS THE LICENSING RIGHTS OF MIV-160

Medivir AB (OMX Nordic: MVIR B) has succeeded in transferring the licensing
agreement on the anti-HIV compound MIV-160 from Guangdong Lantai-Viewland
Pharmaceutical Co. Ltd. to Beijing Mefuvir Medicinal Technology Co. Ltd, a
subsidiary of one of China's largest condom manufacturers. The company will
develop MIV-160 for HIV prophylactic and therapeutic use.  

MIV-160 belongs to the group of polymerase projects which are administered by
its subsidiary Medivir HIV Franchise AB. 

 “The continuing HIV/AIDS epidemic calls for a wide use of condoms with extra
safety.  The annual consumption of condoms in China is 2.8 billion. MIV-160
effectively inactivates HIV when applied as an extra shield of protection on a
condom. All this put together explains why we have chosen to let a dominant
condom producer take on the development of MIV-160” says Prof. Bo Öberg, CEO of
Medivir HIV Franchise AB. 

“In the current situation while China faces a potential HIV epidemic, we see
tremendous opportunities in developing MIV-160 for condom coating, as a vaginal
microbicide and for therapeutic application” comments Zhang Wenyao, Chairman of
the board, Tianjin Human-Care Latex Corporation and Beijing Mefuvir Medicinal
Science Co. Ltd. and Dr. Wang Xuehai, Chairman of the board, Wuhan Humanwell
Hi-Tech Industry Co. Ltd.

The royalty rates and other licensing conditions remain the same as with
Medivir's former partner, but Medivir returns the right to obtain 4% ownership
in Guangdong Lantai-Viewland Pharmaceutical Co. Ltd. and instead receives an
equivalent right to obtain a 5% ownership in Beijing Mefuvir Medicinal
Technology Co. Ltd.

Beijing Mefuvir Medicinal Technology Co. Ltd is a subsidiary to Tianjin
Human-Care Latex Corporation, one of the largest condom manufacturers in China.
Beijing Mefuvir and Tianjin Human-Care Latex Corporation are part of the Wuhan
Humanwell Hi-Tech Industry, traded on the Shanghai Stock Exchange.  






For additional information, please contact
Rein Piir, CFO and VP Investor Relations Medivir, +46 8 5468 3123 or mobile 
+46 708 537292 

For more information about Medivir, please see the company's website,
www.medivir.se

About Wuhan Humanwell Hi-Tech Industry
Wuhan Humanwell Hi-Tech Industry is traded at the Shanghai Stock Exchange
(trading code: 600079) with a market cap of 3.7 billion RMB (June 14 2007). The
Group consists of Wuhan Humanwell Pharmaceutical Co. Ltd.; Yichang Humanwell
Pharmaceutical Co. Ltd.; Hubei Gedian Humanwell Pharmaceutical Co. Ltd.; Huashan
Humanwell Pharmaceutical Co. Ltd.; JISSBON (Wuhan) Sanitary Product Co. Ltd.;
Tianjin Human-Care Latex Corporation; Wuhan DONDE Estate development
corporation. Etc. The Group's principal activities are researching,
manufacturing and selling pharmaceutical and reproductive health care products.
Products are exported to other countries.